sponsored
PatientsVille.com Logo

PatientsVille

Eovist Medical Research Studies

Up-to-date List of Eovist Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Eovist Medical Research Studies

Rank Status Study
1 Recruiting Utility Study of Primovist-MRI on HCC Staging
Condition: Hepatocellular Carcinoma
Intervention: Procedure: Primovist-enhanced MRI
Outcome Measures: incidence of change of BCLC stage after add-on Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.;   Incidence of newly detected intrahepatic HCC lesionss by Primovist-enhanced MRI, but, these lesions were not detected by liver dynamic CT;   Incidence of newly detected intrahepatic benign lesions by Primovist-enhanced MRI, but, these lesions were not detected by liver dynamic CT;   Frequency of change in treatment modality in patients with change of BCLC stage after Primovist-enhanced MRI;   Sensitivity, specificity, false positive predictive value, false negative predictive value, and accuracy of Primovist-enhanced MRI
2 Recruiting 24hr Imaging Of HCC After Eovist
Condition: Hepatocellular Carcinoma
Intervention: Drug: Eovist
Outcome Measure: Calculate the percent absolute enhancement of HCCs following Eovist administration at multiple phases
3 Not yet recruiting Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)
Condition: Liver Neoplasms
Interventions: Drug: Gadoxetate;   Drug: Gadopentetate Dimeglumine
Outcome Measure: Specificity of Contrast Enhanced MRI Using Eovist Versus Combined Use of Eovist and Magnevist
4 Not yet recruiting Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent
Condition: Magnetic Resonance Imaging
Interventions: Drug: Gadoxetate disodium (Eovist/Primovist, BAY 86-4873);   Drug: Sodium chloride solution
Outcome Measures: Number of participants with additional diagnostic information from combined (pre-contrast and post-contrast) compared with pre-contrast images;   Number of participants with adverse events as a measure of safety and tolerability;   Number of participants with serious adverse events as a measure of safety and tolerability;   Number of lesions detected for the pre-contrast images;   Number of lesions detected for the combined images;   Number of participants with contrast enhancement of the biliary system for the combined images;   Contrast enhancement of the biliary system for the combined images assessed by yes or no question;   Number of participants with visualization of the biliary system for the pre-contrast images;   Number of participants with visualization of the biliary system for the combined images;   Number of participants with diagnostic confidence for the pre-contrast images;   Number of participants with diagnostic confidence for the combined images
5 Recruiting Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Eovist;   Procedure: MRI Scan;   Procedure: Percutaneous needle biopsy
Outcome Measure: Uptake of Eovist to evaluate MR contrast enhancements in prostate cancer
6 Unknown  Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases
Condition: Colorectal Liver Metastases
Intervention: Other: MR imaging
Outcome Measures: To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.;   To compare diagnostic performance of MDCT, Diffusion Weighted MR and Primovist-enhanced MRI in the differentiation of viable from non-viable metastatic tumour compared to reference standard of pathology.;   To investigate in the cohort of patients who have pre and post-chemotherapy MRI the role of DWI in predicting treatment response by baseline pretreatment Apparent Diffusion Coefficient (ADC) values.;   To assess performance of Primovist-enhanced MRI, DW-MRI and MDCT in assessment of treatment response following chemotherapy in the cohort of patients who have pre and post-chemotherapy MRI.;   To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.
7 Recruiting The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Radiation: CT scan
Outcome Measure: To obtain bi-directional measurements of hilar cholangiocarcinoma tumor in centimeters, on the Dual Energy CT scan images.
8 Recruiting Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
Outcome Measure: The transfer constant, Ktrans, between intravascular and interstitial compartments.
9 Recruiting Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
Condition: Hepatocellular Carcinoma
Intervention: Drug: GADOXETIC ACID
Outcome Measures: hepatocellular carcinoma diagnosed;   magnetic resonance imaging sensitivity
10 Recruiting Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer
Condition: Hepatocellular Carcinoma
Interventions: Procedure: RFA;   Procedure: Radioembolization (SIRT)
Outcome Measures: time to recurrence;   overall survival;   Primovist®-enhanced MRI is non-inferior or superior compared with contrast-enhanced multislice CT;   quality of life;   safety of RFA;   safety of SIR Spheres
11 Recruiting Functional MRC With Eovist for Acute Cholecystitis
Condition: Acute Cholecystitis
Intervention:
Outcome Measure: Number of positive cases of acute cholecystitis
12 Unknown  Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
Conditions: Colorectal Cancer;   Liver Metastases;   Irradiation Damage;   Radiation Induced Liver Disease
Interventions: Drug: Pentoxifylline;   Drug: Ursodeoxycholic Acid;   Drug: Enoxaparin
Outcome Measures: HDR-brachytherapy isodose (measured in Gy) that corresponds to the metastases without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.;   HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.;   Correlation between the HDR brachytherapy isodose that corresponds to damaged live tissue as defined by missing Gd-EOB-DTPA enhancement in MR imaging and liver-specific laboratory values.;   Quality of live.;   Safety of the study drugs.
13 Unknown  Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging
Conditions: Colorectal Liver Metastasis;   Contrast Enhances Intraoperative Ultrasound;   Imaging for Liver Cancer;   Imaging for Liver Metastasis
Interventions: Procedure: Liver Surgery;   Device: Contrast Enhanced Ultrasound;   Radiation: CT Scan (standard);   Radiation: Primovist MRI (3 Tesla)
Outcome Measures: Detection of Liver Metastasis during Operation;   Comparison of Detection Rate for Liver Metastases of all imaging modalities;   Comparison of Sensitivity of all imaging modalities;   Comparison of Specicivity of all imaging modalities
14 Recruiting Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
Condition: Liver Cancer
Interventions: Drug: iodinated contrast dye;   Drug: motexafin gadolinium;   Other: Eovist-enhanced MRI
Outcome Measures: Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC);   Positive predictive value (PPV) of CT scan vs MRI for diagnosing HCC;   Lesion-level sensitivity and PPV of contrast CT scan vs contrast MRI;   Sensitivity and specificity of multiphase contrast-enhanced CT scan vs MRI for diagnosing residual or recurrent HCC;   Accuracy of imaging-based diagnosis and staging of HCC in clinical practice using the new OPTN liver-imaging criteria compared with the reference standard of pathologic diagnosis and staging at the time of explantation;   Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal)
15 Unknown  Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy
Condition: Hepatocellular Carcinoma
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Eovist etiology and treatment.

A major focus of Eovist research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Eovist